HCMED (6934) reported revenue of NT$44,000 for Oct 2026, -88.5% year on year and -99.9% from the previous month. Revenue for Jan–Oct 2026 was NT$54.7 million (+201.7% year on year).
In Oct 2026, it ranked No. 153 by revenue among 160 Biotech & Medical companies.
Monthly revenue chart
Hover over (or tap) a bar to see that month’s revenue.
Monthly revenue history
| Month | Revenue | YoY | MoM |
|---|---|---|---|
| Oct 2026 | NT$44,000 | -88.5% | -99.9% |
| Sep 2026 | NT$34.8 million | +822.9% | +84,690.2% |
| Aug 2026 | NT$41,000 | -16.3% | -14.6% |
| Jul 2026 | NT$48,000 | -98.4% | -99.6% |
| Jun 2026 | NT$11.6 million | +41,325.0% | +52,622.7% |
| May 2026 | NT$22,000 | -98.8% | -99.5% |
| Apr 2026 | NT$4.5 million | +546.6% | +24.3% |
| Mar 2026 | NT$3.6 million | -53.1% | +20,044.4% |
| Feb 2026 | NT$18,000 | -91.2% | -56.1% |
| Jan 2026 | NT$41,000 | -88.3% | -99.6% |
| Dec 2025 | NT$11.3 million | +721.3% | -84.1% |
| Nov 2025 | NT$70.8 million | +3,217.2% | +18,488.7% |
| Oct 2025 | NT$381,000 | -99.6% | -89.9% |
| Sep 2025 | NT$3.8 million | +3.2% | +7,587.8% |
| Aug 2025 | NT$49,000 | -95.6% | -98.4% |
| Jul 2025 | NT$3.1 million | -76.1% | +10,910.7% |
| Jun 2025 | NT$28,000 | -99.2% | -98.5% |
| May 2025 | NT$1.9 million | -39.9% | +165.7% |
| Apr 2025 | NT$697,000 | -82.9% | -91.0% |
| Mar 2025 | NT$7.7 million | +103.9% | +3,667.8% |
| Feb 2025 | NT$205,000 | -90.7% | -41.3% |
| Jan 2025 | NT$349,000 | -85.2% | -74.6% |
| Dec 2024 | NT$1.4 million | -46.8% | -35.7% |
| Nov 2024 | NT$2.1 million | -16.3% | -97.9% |
| Oct 2024 | NT$101.7 million | +26,049.6% | +2,686.9% |
Jan–Oct 2026 cumulative: NT$54.7 million (+201.7% YoY)
Other Biotech & Medical companies
Compare with peers: HCMED vs PEC / HCMED vs Lotus Pharm / HCMED vs Bora
| Company | Revenue | YoY |
|---|---|---|
| PEC | NT$2.84 billion | +102.0% |
| Lotus Pharm | NT$2.13 billion | -22.5% |
| Bora | NT$1.99 billion | +15.9% |
| Great Tree Pharmacy | NT$1.67 billion | +1.5% |
| EXCELSIOR | NT$1.02 billion | +38.6% |
| PEGAVISION | NT$793 million | +13.0% |
| Synmosa Biopharma | NT$766.6 million | +41.2% |
| Y.S.H. | NT$749.4 million | +4.4% |
Company remark (original Chinese)
差異主係本公司9月完成與新藥廠客戶簽約所依約完成事項而取得的勞務報酬所致;勞務報酬非定期,依照合約進行並認列。
See also
← All Taiwan listed & OTC companies
Sources: Taiwan Stock Exchange, monthly revenue of listed companies (Government Open Data Platform); Taipei Exchange, monthly revenue of OTC companies (TPEx OpenAPI); historical months from MOPS. Amounts in New Taiwan dollars. Changes calculated by this site from the source figures. Not investment advice. Updated: 2026-11-16